Overview
The purpose of this study is to compare standard treatment and fusion ontogenetic surgery (total mesometrial resection, laterally extended endopelvic resection, peritoneal mesometrial resection) for gynecologic cancer in order to evaluate treatment response, adverse effect and survival.
Description
Fujii method and ontogenetic surgery are the surgical method of radical hysterectomy that can preserve pelvic organ function as much as possible.
Fujii method has advantage of preserving pelvic autonomic nerve with radical resection of tissue under parametrium. And ontogenetic surgery has advantage of reducing need of radiation therapy by radical resection of tissue above parametrium.
This study is prospective study for fusion ontogenetic surgery that has the advantage of both Fujji method and ontogenetic surgery.
Eligibility
Inclusion Criteria:
- Female, Age ≥ 20 years
- Patients with primary, recurrent, or refractory cervical cancer (FIGO stage IB1-IVA), primary, recurrent, or refractory uterine cancer (FIGO stage IA, grade 3, IB-IVA), or gynecologic cancer patients showing pelvic sidewall recurrence.
- ECOG performance status 0 or 1
- Extensive surgery might be expected to cure the disease, or expected to relieve severe pelvic pain.
- Patients who signed an approved informed consent
- Patients who do not have a treatment option other than surgery.
Exclusion Criteria:
- Female, Age < 20 years
- ECOG performance status ≥2
- Bilateral pelvic sidewall invasion
- Patients who had undergone radical hysterectomy, trachelectomy, or hysterectomy in case of the primary disease.
- Patients who refused to sign an informed consent